Publicaciones en las que colabora con Salvador Martín Algarra (15)

2018

  1. Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients

    Annals of Oncology, Vol. 29, Núm. 5, pp. 1312-1319

2017

  1. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients

    Annals of Oncology, Vol. 28, Núm. 8, pp. 1988-1995

2015

  1. Assessment of EGFR and KRAS mutation status from FNAs and core-needle biopsies of non-small cell lung cancer

    Cancer Cytopathology, Vol. 123, Núm. 4, pp. 230-236

  2. Variations in molecular profile in NSCLC can be analyzed using cytological samples: Development of EGFR resistance mutations and coexistence of ALK-EML4 translocation in an EGFR-sensitive patient

    International Journal of Surgical Pathology, Vol. 23, Núm. 2, pp. 111-115

2014

  1. Randomized pharmacokinetic study comparing subcutaneous and intravenous palonosetron in cancer patients treated with platinum based chemotherapy

    PLoS ONE, Vol. 9, Núm. 2

2011

  1. Assessment of epidermal growth factor receptor and krasmutation status in cytological stained smears of non-small celllung cancer patients: Correlation with clinical outcomes

    Oncologist, Vol. 16, Núm. 6, pp. 877-885

2007

  1. Carcinoma microcítico de pulmón

    Revista de medicina, Vol. 51, Núm. 2, pp. 7-13

  2. Randomized crossover pharmacokinetic evaluation of subcutaneous versus intravenous granisetron in cancer patients treated with platinum-based chemotherapy

    Oncologist, Vol. 12, Núm. 9, pp. 1151-1155

  3. Small-cell lung cancer

    Revista de medicina de la Universidad de Navarra, Vol. 51, Núm. 2, pp. 7-13

2005

  1. Activity of gefitinib in central nervous system metastases in patients with non-small-cell lung center: Two case reports and a review of the literature

    Clinical Lung Cancer, Vol. 7, Núm. 2, pp. 138-140

  2. Assessment of the value of confirming responses in clinical trials in oncology

    European Journal of Cancer, Vol. 41, Núm. 11, pp. 1528-1532

2004

  1. Paclitaxel, cisplatin, and vinorelbine combination chemotherapy in metastatic non-small-cell lung cancer

    American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 27, Núm. 3, pp. 299-303

2003

  1. Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer

    Oncology, Vol. 64, Núm. 1, pp. 28-35

2002

  1. Comparison of unidimensional and bidimensional measurements in metastatic non-small cell lung cancer

    British Journal of Cancer, Vol. 87, Núm. 2, pp. 158-160

1996

  1. High-dose BCNU and autologous progenitor cell transplantation given with intra-arterial cisplatinum and simultaneous radiotherapy in the treatment of high-grade gliomas: Benefit for selected patients

    Bone Marrow Transplantation, Vol. 18, Núm. 1, pp. 143-149